Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation

Mauro Zaccarelli, Carlo Federico Perno, Federica Forbici, Antonella Cingolani, Guiseppina Liuzzi, Ada Bertoli, Maria Paola Trotta, Maria Concetta Bellocchi, Simona Di Giambenedetto, Valerio Tozzi, Caterina Gori, Roberta D'Arrigo, Patrizio De Longis, Pasquale Noto, Enrico Girardi, Andrea De Luca, Andrea Antinori

Research output: Contribution to journalArticle


Objective: M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment. Methods: Overall, 211 patients were selected from a database of HIV patients undergoing genotypic resistance test after virological failure of HAART regimens in two major reference centres in Rome between 1999 and 2001. At the time of genotyping, 120 of them (56.9%) were failing a 3TC-including HAART, while 91 (43.1%) received 3TC only in previous HAART. Duration of the current 3TC-containing regimen and the time from the end of last 3TC treatment to genotypic resistance test (GRT) were analysed. Results: Among patients currently undergoing 3TC-containing HAART, the prevalence of M184V/I was 82.5% (78.3/4.2%, respectively) and significantly associated to current 3TC use at GRT. Prevalence of M184V/I was associated to longer history of 3TC (from 47.1% in patients treated with 3TC for 42 months of current 3TC carried M184V. At logistic regression analysis, the rate of increase of M184V/I in 3TC-failing patients was statistically significant (OR: 1.066 per month of current 3TC therapy, 95% CI: 1.020-1.114, P

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalAntiviral Therapy
Issue number1
Publication statusPublished - Feb 2003


ASJC Scopus subject areas

  • Pharmacology

Cite this